These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31448450)

  • 21. Quality improvement to evaluate and provide treatment for chronic hepatitis C postpartum.
    Behnke C; Nissim O; Simerlein W; Beeker K; Tarleton JL; Lazenby GB
    J Am Pharm Assoc (2003); 2022; 62(3):864-869. PubMed ID: 34975005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
    Chhatwal J; He T; Lopez-Olivo MA
    Pharmacoeconomics; 2016 Jun; 34(6):551-67. PubMed ID: 26748919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens.
    Li H; Tan JL; Li JR; Liu NN; Chen JH; Lv XQ; Zou LL; Dong B; Peng ZG; Jiang JD
    Biomed Pharmacother; 2019 Aug; 116():108976. PubMed ID: 31103827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature.
    Mikolasevic I; Kanizaj TF; Bozic D; Puz P; Shapeski SS; Puljiz Z; Radic-Kristo D; Lalovac M; Mijic M; Delija B; Juric T; Bogadi I; Virovic-Jukic L
    Curr Drug Metab; 2021; 22(2):89-98. PubMed ID: 33319667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection.
    Néant N; Solas C
    Int J Antimicrob Agents; 2020 Jul; 56(1):105571. PubMed ID: 30394302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
    Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
    Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents?
    Du P; Wang X; Kong L; Jung J
    Telemed J E Health; 2021 May; 27(5):488-494. PubMed ID: 32882154
    [No Abstract]   [Full Text] [Related]  

  • 28. Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.
    Safarnezhad Tameshkel F; Karbalaie Niya MH; Zamani F; Motamed N; Ajdarkosh H; Vafaeimanesh J; Khoonsari M; Sohrabi MR; Aten S; Azarkeivan A; Eslami MS; Perumal D; Maadi M; Ghanbari B; Keyvani H
    Arch Virol; 2020 Oct; 165(10):2193-2203. PubMed ID: 32638116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals.
    Palanisamy N; Kalaghatgi P; Akaberi D; Lundkvist Å; Chen ZW; Hu P; Lennerstrand J
    Antivir Ther; 2018; 23(6):485-493. PubMed ID: 29745936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pushing to a cure by harnessing innate immunity against hepatitis C virus.
    Ireton RC; Gale M
    Antiviral Res; 2014 Aug; 108():156-64. PubMed ID: 24907428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Micro-elimination of hepatitis C through testing of Egyptian pregnant women presenting at delivery: implications for screening policies.
    Mostafa A; Ebeid FSE; Khaled B; Ahmed RHM; El-Sayed MH
    Trop Med Int Health; 2020 Jul; 25(7):850-860. PubMed ID: 32306545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients.
    Pérez-Matute P; Íñiguez M; Villanueva-Millán MJ; Recio-Fernández E; Vázquez AM; Sánchez SC; Morano LE; Oteo JA
    Eur J Intern Med; 2019 Sep; 67():47-58. PubMed ID: 31221551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress and Barriers Towards Elimination of Chronic Hepatitis C in Children.
    Pluta M; Pokorska-Śpiewak M; Aniszewska M; Kowalik-Mikołajewska B; Marczyńska M
    Klin Padiatr; 2021 Sep; 233(5):211-215. PubMed ID: 33339066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. When Coadministration Cannot Be Avoided: Real World Experience of Direct Acting Antivirals for the Treatment of Hepatitis C Virus Infection in Patients on First Generation Anticonvulsants.
    Natali KM; Jimenez HR; Slim J
    J Pharm Pract; 2022 Jun; 35(3):495-499. PubMed ID: 33317381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.
    Al-Khazraji A; Patel I; Saleh M; Ashraf A; Lieber J; Malik R
    Dig Dis; 2020; 38(1):46-52. PubMed ID: 31422405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure.
    Sagnelli E; Starace M; Minichini C; Pisaturo M; Macera M; Sagnelli C; Coppola N
    Infection; 2018 Dec; 46(6):761-783. PubMed ID: 30084057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
    Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
    BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.
    Wu S; Kanda T; Nakamoto S; Imazeki F; Yokosuka O
    World J Gastroenterol; 2013 Dec; 19(47):8940-8. PubMed ID: 24379619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.